Scarica l'app Stockscreener
46.88
0.80%
-0.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$47.26
Aprire:
$47.54
Volume 24 ore:
4.22M
Relative Volume:
0.55
Capitalizzazione di mercato:
$18.60B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-5.7548
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
-4.40%
1M Prestazione:
-15.68%
6M Prestazione:
+97.64%
1 anno Prestazione:
+75.45%
Intervallo 1D:
$46.77
$48.35
Intervallo di 1 settimana:
$45.62
$50.50
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
46.88 | 18.75B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications - foreignpolicyjournal.com
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in Stock - MarketBeat
Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise - Stock Titan
Moderna’s mRNA flu shot to get FDA review - The Hill
Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue RulesWhat's Changed - Yahoo Finance
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm - BioSpace
Understanding Momentum Shifts in (MRNA) - Stock Traders Daily
Total liabilities & shareholders' equities of Moderna, Inc. – BVL:MRNAUS - TradingView
ASCO26: Merck & Co., Moderna detail melanoma survival findings for cancer vaccine - FirstWord Pharma
CapEx per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna stock (US60770K1034): analysts turn cautious after sharp 2026 rebound - AD HOC NEWS
Moderna mRNA flu vaccine to get FDA panel review - The Hill
FDA plans rare advisory hearing to debate Moderna’s flu shot - The Boston Globe
EBITDA per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Merck cancer combo cuts melanoma spread risk at five years - Reuters
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna's mRNA flu shot to face FDA panel in June - FirstWord Pharma
Moderna Flu Shot Heads To FDA Advisory PanelModerna (NASDAQ:MRNA) - Benzinga
Moderna, Inc. Income Statement – BVL:MRNAUS - TradingView
Asset turnover of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Inc. Cash Flow – BVL:MRNAUS - TradingView
MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot - Yahoo Finance
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Flu Vaccine Review Scheduled by FDA for June 2024 - GuruFocus
Moderna's (MRNA) Flu Vaccine Set for FDA Advisory Panel Review - GuruFocus
Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June - marketscreener.com
US FDA to hold expert committee meeting to review Moderna's flu vaccine - Reuters
Moderna to face FDA AdCom review for flu shot (MRNA:NASDAQ) - Seeking Alpha
FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot - Bloomberg.com
Forget Moderna: This biotech juggernaut is a way better buy right now - MSN
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
Moderna, Inc. Trade Ideas — LSX:A2N9D9 - TradingView
Moderna stock (US60770K1034): Hantavirus headlines, Q1 revenue beat and lingering volatility - AD HOC NEWS
Moderna's revenues see strong international momentum in Q1 earnings - MSN
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform - BioSpace
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain - TradingView
ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
CHINA SHOTO : 15000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus - AD HOC NEWS
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds - The Globe and Mail
Moderna’s SWOT analysis: biotech stock faces profitability test - Investing.com
Invesco S&P 500 Equal Weight Income Advantage ETF's Moderna Inc(MRNA) Holding History - GuruFocus
Transcript : Moderna, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10 - marketscreener.com
MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress - TradingView
Moderna Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Moderna stock (US60770K1034): Insider sale adds to a volatile setup - AD HOC NEWS
Moderna president Stephen Hoge sells $2.58m in shares - Investing.com
Moderna (MRNA) president sells 53,336 shares after option exercises - Stock Titan
HHS rescinds vaccine panel charter citing 'administrative error' - Seeking Alpha
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
May 21 '26 |
Sale |
46.84 |
9,263 |
433,879 |
3,924 |
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):